Preclinical therapeutic efficacy of a novel blood-brain barrier-penetrant dual PI3K/mTOR inhibitor with preferential response in PI3K/PTEN mutant glioma

Dimpy Koul(The University of Texas MD Anderson Cancer Center), W.K. Alfred Yung(The University of Texas MD Anderson Cancer Center)
Oncotarget
February 21, 2017
Cited by 21


Related Papers